Endothelial cells (EC) are targets in gene therapy and regenerative medicine, but they are inefficiently transduced with adeno-associated virus (AAV) vectors of various serotypes. To identify barriers hampering efficient transduction and to develop an optimized AAV variant for EC transduction, we screened an AAV serotype 2-based peptide display library on primary human macrovascular EC. Using a new high-throughput selection and monitoring protocol, we identified a capsid variant, AAV-VEC, which outperformed the parental serotype as well as first-generation targeting vectors in EC transduction. AAV vector uptake was improved, resulting in significantly higher transgene expression levels from single-stranded vector genomes detectable within a few hours post-transduction. Notably, AAV-VEC transduced not only proliferating EC but also quiescent EC, although higher particle-per-cell ratios had to be applied. Also, induced pluripotent stem cell-derived endothelial progenitor cells, a novel tool in regenerative medicine and gene therapy, were highly susceptible toward AAV-VEC transduction. Thus, overcoming barriers by capsid engineering significantly expands the AAV tool kit for a wide range of applications targeting EC.
Get full access to this article
View all access options for this article.
References
1.
GrimmD, BuningH. Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum Gene Ther, 2017; 28:1075–1086.
2.
DomengerC, GrimmD.Next-generation AAV vectors—don't judge a virus (only) by its cover. Hum Mol Genet, 2019 [Epub ahead of print]; DOI: 10.1093/hmg/ddz148.
3.
KeelerAM, FlotteTR. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here?. Annu Rev Virol, 2019 [Epub ahead of print]; DOI: 10.1146/annurev-virology-092818-015530.
4.
ColellaP, RonzittiG, MingozziF. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev, 2018; 8:87–104.
5.
BuningH, HuberA, ZhangL, et al.Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol, 2015; 24:94–104.
6.
NathwaniAC, ReissUM, TuddenhamEG, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
7.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
8.
SallachJ, Di PasqualeG, LarcherF, et al.Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther, 2014; 22:929–939.
9.
PandyaJ, OrtizL, LingC, et al.Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol, 2014; 92:116–123.
10.
BuchholzCJ, FriedelT, BuningH. Surface-engineered viral vectors for selective and cell type-specific gene delivery. Trends Biotechnol, 2015; 33:777–790.
11.
PeraboL, BuningH, KoflerDM, et al.In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther, 2003; 8:151–157.
12.
MullerOJ, KaulF, WeitzmanMD, et al.Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol, 2003; 21:1040–1046.
13.
WeinmannJ, GrimmD. Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes, 2017; 53:707–713.
14.
NaumerM, Popa-WagnerR, KleinschmidtJA. Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction. J Gen Virol, 2012; 93:2131–2141.
15.
HristovM, WeberC. Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res, 2008; 58:148–151.
16.
PillayS, MeyerNL, PuschnikAS, et al.An essential receptor for adeno-associated virus infection. Nature, 2016; 530:108–112.
17.
KoflerDM, BuningH, MayrC, et al.Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther, 2004; 11:1416–1424.
18.
NicklinSA, BueningH, DishartKL, et al.Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther, 2001; 4:174–181.
19.
GirodA, RiedM, WobusC, et al.Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med, 1999; 5:1052–1056.
20.
HackerUT, WingenfeldL, KoflerDM, et al.Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med, 2005; 7:1429–1438.
21.
HackerUT, GernerFM, BuningH, et al.Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors. Gene Ther, 2001; 8:966–968.
22.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
23.
HoselM, LuciforaJ, MichlerT, et al.Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo. Hepatology, 2014; 59:2110–2120.
24.
HoffmannD, SchottJW, GeisFK, et al.Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells. Gene Ther, 2017; 24:298–307.
25.
OrlovaVV, DrabschY, FreundC, et al.Functionality of endothelial cells and pericytes from human pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish xenografts. Arter Thromb Vasc Biol, 2014; 34:177–186.
26.
RossiA, DupatyL, AillotL, et al.Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep, 2019; 9:3631.
27.
SenS, ConroyS, HynesSO, et al.Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5. J Gene Med, 2008; 10:143–151.
28.
VaradiK, MichelfelderS, KorffT, et al.Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther, 2012; 19:800–809.
29.
SummerfordC, SamulskiRJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 1998; 72:1438–1445.
30.
AsokanA, HamraJB, GovindasamyL, et al.Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol, 2006; 80:8961–8969.
31.
SummerfordC, BartlettJS, SamulskiRJ. AlphaVbeta5 integrin a co-receptor for adeno-associated virus type 2 infection. Nat Med, 1999; 5:78–82.
32.
LevyHC, BowmanVD, GovindasamyL, et al.Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol, 2009; 165:146–156.
33.
McCartyDM.Self-complementary AAV vectors; advances and applications. Mol Ther, 2008; 16:1648–1656.
34.
WhiteSJ, NicklinSA, BuningH, et al.Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation, 2004; 109:513–519.
35.
WorkLM, BuningH, HuntE, et al.Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther, 2006; 13:683–693.
36.
WhiteK, BuningH, KritzA, et al.Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther, 2008; 15:443–451.
37.
WaterkampDA, MullerOJ, YingY, et al.Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med, 2006; 8:1307–1319.
38.
NaumerM, YingY, MichelfelderS, et al.Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions. Hum Gene Ther, 2012; 23:492–507.
39.
KorbelinJ, SieberT, MichelfelderS, et al.Pulmonary targeting of adeno-associated viral vectors by next-generation sequencing-guided screening of random capsid displayed peptide libraries. Mol Ther, 2016; 24:1050–1061.
40.
BuningH, SrivastavaA. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev, 2019; 12:248–265.
41.
PeraboL, GoldnauD, WhiteK, et al.Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol, 2006; 80:7265–7269.
42.
UhrigS, CoutelleO, WieheT, et al.Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther, 2012; 19:210–218.
43.
DudekAM, PillayS, PuschnikAS, et al.An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor. J Virol, 2018; 92:e02213-17.
44.
MeyerNL, HuG, DavulcuO, et al.Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR. Elife, 2019; 8:e44707.
45.
ZhangR, CaoL, CuiM, et al.Adeno-associated virus 2 bound to its cellular receptor AAVR. Nat Microbiol, 2019; 4:675–682.
46.
LaurenzanaA, BiagioniA, D'AlessioS, et al.Melanoma cell therapy: endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget, 2014; 5:3711–3727.
47.
PurwantiYI, ChenC, LamDH, et al.Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model. Stem Cells Transl Med, 2014; 3:923–935.
48.
ZhangJX, KangCS, ShiL, et al.Use of thymidine kinase gene-modified endothelial progenitor cells as a vector targeting angiogenesis in glioma gene therapy. Oncology, 2010; 78:94–102.
49.
Wiktorowska-OwczarekA, NamiecinskaM, BalcerczykA, et al.Human micro- and macrovessel-derived endothelial cells: a comparative study on the effects of adrenaline and a selective adenosine A2-type receptor agonist under normoxic and hypoxic conditions. Pharmacol Rep, 2007; 59:800–806.
50.
CochraneA, AlbersHJ, PassierR, et al.Advanced in vitro models of vascular biology: human induced pluripotent stem cells and organ-on-chip technology. Adv Drug Deliv Rev, 2019; 140:68–77.
51.
ViemannD, GoebelerM, SchmidS, et al.TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. J Leukoc Biol, 2006; 80:174–185.
52.
MietzschM, BroeckerF, ReinhardtA, et al.Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol, 2014; 88:2991–3003.
DevanesanAJ, LaughlanKA, GirnHR, et al.Endothelial progenitor cells as a therapeutic option in peripheral arterial disease. Eur J Vasc Endovasc Surg, 2009; 38:475–481.
55.
WerlingNJ, ThorpeR, ZhaoY. A systematic approach to the establishment and characterization of endothelial progenitor cells for gene therapy. Hum Gene Ther Methods, 2013; 24:171–184.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
